CYPFLIT E 35 contains Cyproterone Acetate 2 mg + Ethinylestradiol 0.035 mg, a hormonal combination used in selected androgen-dependent dermatological and gynaecological conditions. A differentiated PCD Pharma Gynae product.
Selected androgen-related conditions such as acne/hirsutism and contraception when specifically appropriate.
No, suitability must be assessed by a physician.
Assess personal and family history of thrombosis and cardiovascular risk before use. Seek urgent medical attention for leg swelling, chest pain or sudden breathlessness.
Nausea, headache, breast tenderness, mood changes, fluid retention and menstrual changes may occur. Combined hormonal therapy may increase thromboembolic risk in susceptible women.
CYPFLIT E 35: Cyproterone acetate has antiandrogenic activity, while Ethinylestradiol suppresses ovarian androgen production and regulates hormonal activity.
